Galapagos NV
↗Mechelen, Belgium
Galapagos NV is a fully integrated, clinical-stage biotechnology company headquartered in Mechelen, Belgium. The company focuses on the discovery, development, and commercialization of innovative medicines to address high unmet medical needs, with a primary strategic focus on immunology and oncology.
Galapagos leverages a proprietary target discovery platform to identify novel modes of action. Following significant strategic restructuring in 2025 and 2026, the company has refocused its pipeline, including the wind-down of its cell therapy activities, to prioritize sustainable growth and value creation through transformational transactions and clinical program development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$1.25B (TTM)
Founded:1999
Ownership:public
Status:operating
FUNDING
Total Raised:$136M
Investors:Gilead Sciences
STOCK
Exchange:Euronext Amsterdam, NASDAQ
Ticker:GLPG
Market Cap:$1.88B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Galapagos Biopharma Belgium BV, Galapagos SASU, Galapagos B.V., Galapagos Inc.
Key Partnerships:Gilead Sciences (long-term R&D collaboration)
COMPETITION
Position:Challenger
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, C4 Therapeutics
LEADERSHIP
Key Executives:
Henry O. Gosebruch - CEO
Jérôme Contamine - Chairman of the Board
LINKS
Website:glpg.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Galapagos NV and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Galapagos NV. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.